Article information
Full text is only aviable in PDF
References
[1]
Idiopathic pulmonary fibrosis.
International Consensus Statement.
Am J Respir Crit Care Med, 161 (2000), pp. 646-664
[2]
A Xaubet, J Ancoechea, R Blanquer, C Montero, F Morell, F Rodríguez-Becerra, et al.
Diagnóstico y tratamiento de las enfermedades intersticiales difusas.
Arch Bronconeumol, 39 (2003), pp. 580-600
[3]
D Lynch, W Travis, N Müller, J Galvin, D Hansell, P Grenier, et al.
Idiopathic interstitial pneumonias: CT features.
Radiology, 236 (2005), pp. 10-21
[4]
K Flaherty, G Toews, W Travis, T Colby, E Kazerooni, B Gross, et al.
Clinical significance of histological classification of idiopathic interstitial pneumonia.
Eur Respir J, 19 (2002), pp. 275-283
[5]
P Noble, R Homer.
Idiopathic pulmonary fibrosis: new insights into pathogenesis.
Clin Chest Med, 25 (2004), pp. 749-758
[6]
KM Antoniou, MG Alexandrakis, NM Siafakas, D Bouros.
Cytokine network in the pathogenesis of idiopathic pulmonary fibrosis.
Sarcoidosis Vase Diffuse Lung Dis, 22 (2005), pp. 91-104
[7]
N Kohno, Y Awaya, T Oyama, M Yamakido, M Akiyama, Y Inoue, et al.
KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease.
Am Rev Respir Dis, 148 (1993), pp. 637-642
[8]
K Yamane, H Ihn, M Kubo, N Yasawa, K Kikuchi, Y Soma, et al.
Serum levels of KL-6 as a useful marker evaluating pulmonary fibrosis in patients with systemic sclerosis.
J Rheumatol, 27 (2000), pp. 930-934
[9]
A Yokohama, N Khono, H Hamada, M Sakatani, E Ueda, K Kondo, et al.
Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 158 (1998), pp. 1680-1684
[10]
M Selman, V Ruiz, S Cabrera, L Segura, R Ramírez, R Barrios, et al.
TIMP-1,-2,-3 and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?.
Am J Physiol Lung Cell Mol Physiol, 279 (2000), pp. 562-574
[11]
M Winkler, J Fowlkes.
Metalloproteinase and growth factor interactions; do they play a role in pulmonary fibrosis?.
Am J Physiol Lung Cell Mol Physiol, 283 (2002), pp. 1-11
[12]
M Suga, K Yyonaga, H Ichiasu, N Saita, H Yamasaki, M Ando.
Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases.
Eur Respir J, 14 (1999), pp. 376-382
[13]
H Takahashi, T Fujishima, H Koba, S Murakami, K Kurokawa, Y Shibuya, et al.
Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent.
Am J Respir Crit Care Med, 162 (2000), pp. 1109-1114
[14]
K Greene, TE King Jr, Y Kuroki, B Bucher-Bartelson, GW Hunninghake, LS Newman, et al.
Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis.
Eur Respir J, 19 (2002), pp. 439-446
[15]
H Ohnishi, A Yokohama, K Kondo, H Hamada, M Abe, K Nishimura, et al.
Comparative study of KL-6, SP-A, SP-D and MCP-1 as serum markers for interstitial lung diseases.
Am J Respir Crit Care Med, 165 (2002), pp. 378-381
[16]
M Nakayama, H Sayoh, H Ishikawa, M Fujiwara, H Kamma, M Ohtsuka, et al.
Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases.
Chest, 123 (2003), pp. 2001-2006
[17]
PJ Sime, RA Marr, D Gauldie, et al.
Transfer of TNF-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta 1 and myofibroblasts.
Am J Pathol, 153 (1998), pp. 825-832
[18]
W Border, N Noble.
Transforming growth factor β in tissue fibrosis.
N Engl J Med, 331 (1994), pp. 1286-1294
[19]
Y Suk-Joong, AH Adlakha, A Limper.
Circulating transforming factor β. A potential marker of the disease activity during idiopathic pulmonary fibrosis.
Chest, 120 (2001), pp. 68S-70S
Copyright © 2006. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
